# Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

> **NCT02282358** · PHASE1,PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma
- Relapsed and Refractory
- Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

## Interventions

- **DRUG:** Mocetinostat

## Key facts

- **NCT ID:** NCT02282358
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282358, "Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02282358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*